Matinas Biopharma Hl (MTNB)

Feb 13, 2025, 5:00 PM EST - 9 days ago

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Feb 7, 2025, 7:30 AM EST - 15 days ago

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

Jan 10, 2025, 5:15 PM EST - 6 weeks ago

Matinas BioPharma Receives NYSE Noncompliance Notice

Oct 31, 2024, 6:30 AM EDT - 4 months ago

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Aug 14, 2024, 9:40 PM EDT - 6 months ago

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 6 months ago

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 7, 2024, 7:00 AM EDT - 7 months ago

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

Jun 24, 2024, 8:30 AM EDT - 8 months ago

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Jun 13, 2024, 7:00 AM EDT - 9 months ago

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.

May 16, 2024, 7:00 AM EDT - 10 months ago

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

May 9, 2024, 7:47 PM EDT - 10 months ago

Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 10 months ago

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

May 2, 2024, 7:00 AM EDT - 10 months ago

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

Apr 3, 2024, 8:30 AM EDT - 11 months ago

Matinas BioPharma Prices $10 Million Registered Direct Offering

Mar 28, 2024, 11:20 PM EDT - 11 months ago

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 4:05 PM EDT - 11 months ago

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Mar 25, 2024, 8:00 AM EDT - 11 months ago

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

Mar 22, 2024, 9:15 AM EDT - 1 year ago

Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Mar 22, 2024, 6:30 AM EDT - 1 year ago

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Feb 20, 2024, 7:30 AM EST - 1 year ago

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Dec 27, 2023, 7:30 AM EST - 1 year ago

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Dec 21, 2023, 7:30 AM EST - 1 year ago

Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

Nov 8, 2023, 10:44 PM EST - 1 year ago

Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:30 AM EST - 1 year ago

Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Oct 12, 2023, 11:26 AM EDT - 1 year ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX TPST

Oct 11, 2023, 7:30 AM EDT - 1 year ago

Patient with Candida krusei Infection in Matinas BioPharma's Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

Sep 28, 2023, 7:00 AM EDT - 1 year ago

Matinas BioPharma to Present at Two Investment Conferences in October 2023

Sep 27, 2023, 7:00 AM EDT - 1 year ago

Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek

Sep 22, 2023, 5:25 PM EDT - 1 year ago

Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference

Aug 22, 2023, 7:30 AM EDT - 1 year ago

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

Aug 2, 2023, 7:00 AM EDT - 1 year ago

Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023

Jul 26, 2023, 8:00 AM EDT - 1 year ago

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023

May 11, 2023, 7:30 AM EDT - 1 year ago

Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023

May 10, 2023, 7:23 PM EDT - 1 year ago

Matinas BioPharma Holdings, Inc. (MTNB) Q1 2023 Earnings Call Transcript

May 10, 2023, 4:05 PM EDT - 1 year ago

Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update

May 3, 2023, 7:00 AM EDT - 1 year ago

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023

Mar 15, 2023, 8:26 PM EDT - 2 years ago

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call Transcript

Mar 15, 2023, 4:05 PM EDT - 2 years ago

Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

Mar 8, 2023, 7:00 AM EST - 2 years ago

Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023

Mar 2, 2023, 7:00 AM EST - 2 years ago

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

Jan 30, 2023, 4:01 PM EST - 2 years ago

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Jan 23, 2023, 7:00 AM EST - 2 years ago

Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023

Jan 17, 2023, 10:30 AM EST - 2 years ago

Adolore Biotherapeutics Strengthens Management Team and Board of Directors with the Appointments of Roelof Rongen, MSE, MBA and Mark C. Rogers, MD, MBA

Jan 12, 2023, 7:00 AM EST - 2 years ago

Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids

Nov 2, 2022, 8:43 PM EDT - 2 years ago

Matinas BioPharma Holdings, Inc. (MTNB) Q3 2022 Earnings Call Transcript

Nov 2, 2022, 4:02 PM EDT - 2 years ago

Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Oct 21, 2022, 7:48 AM EDT - 2 years ago

Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Oct 21, 2022, 7:00 AM EDT - 2 years ago

Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

Oct 19, 2022, 7:10 AM EDT - 2 years ago

Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022